IL2 and autoimmune hepatitis: Descriptions of all AILD blood and liver explant donors whose PBMC and LIL were used in these and subsequent studies in this paper to address the effect of IL‐2 on phenotype are given in Tables 1 and 2 [blood donors were: AIH = 20 (aged 44·4 ± 13·8 years, disease in remission = 14, disease in flare up/relapse = 6); PSC = 3 (aged 58·0 ± 17·3 years); PBC = 10 (aged 54·0 ± 9·6 years); control = 9 (aged 55·1 ± 11·9 years)].